Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,084 across all filing types
Latest filing 2026-02-11 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于召开2026年第一次临时股东会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2026 first extraordinary general meeting of shareholders for a company, detailing the meeting time, voting procedures, proposals to be voted on, and instructions for proxy voting. It includes information about the meeting agenda, voting codes, and legal compliance references. There are no financial statements or detailed financial data present. The document is primarily an announcement and procedural notice for a shareholders meeting rather than a report or transcript. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2026-02-11 Chinese
第四届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's fourth board of directors' third meeting. It details the meeting's attendance, the agenda items discussed, voting results, and references to further shareholder meetings and related announcements. The content focuses on board decisions, including approval of stock incentive plans and authorization requests to the shareholders. There are no financial statements or detailed financial performance data present. The document is not a full annual or interim report, nor is it a transcript or earnings release. It is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is 3630 characters, which is consistent with a meeting resolution announcement rather than a full report.
2026-02-11 Chinese
2026年限制性股票激励计划（草案）
Remuneration Information Classification · 95% confidence The document is titled "西藏易明西雅医药科技股份有限公司 2026 年限制性股票激励计划（草案）" which translates to "Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. 2026 Restricted Stock Incentive Plan (Draft)". It details a stock incentive plan involving restricted stock awards to directors, senior management, and key employees. The document includes legal references, plan objectives, management structure, eligibility criteria, stock quantities, grant prices, vesting and lock-up periods, performance conditions, and other governance and procedural details related to the stock incentive plan. It is a comprehensive plan document outlining the terms and conditions of a stock-based compensation scheme. This type of document is neither a financial report, earnings release, nor a regulatory announcement about voting or capital changes. It is a detailed management and governance-related disclosure about executive compensation and incentive arrangements. According to the filing definitions, such detailed compensation and incentive plan disclosures fall under "Remuneration Information (DEF 14A)" filings, which cover reports detailing compensation for top executives and directors. Therefore, the correct classification is DEF 14A with high confidence.
2026-02-11 Chinese
2026年限制性股票激励计划（草案）摘要
Remuneration Information Classification · 95% confidence The document is a detailed summary of a 2026 restricted stock incentive plan (股权激励计划) for 西藏易明西雅医药科技股份有限公司. It includes extensive information about the plan's purpose, management, scope, conditions, stock quantities, pricing, vesting schedules, performance targets, and legal compliance. The content is focused on the company's stock-based employee incentive program, which is a form of remuneration and compensation for directors, senior management, and key employees. It is not a financial report, earnings release, or regulatory filing about financial results or corporate governance changes. Instead, it is a remuneration-related document detailing compensation plans for executives and employees. Therefore, the most appropriate classification is Remuneration Information (DEF 14A). The document length (15,000 characters) and detailed content confirm it is the plan itself, not just an announcement or summary, so it is not RPA or RNS.
2026-02-11 Chinese
北京植德律师事务所关于西藏易明西雅医药科技股份有限公司2026年限制性股票激励计划的法律意见书
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a 2026 restricted stock incentive plan for a listed company, 西藏易明西雅医药科技股份有限公司. It extensively discusses the legal compliance, procedures, eligibility, stock quantities, pricing, vesting conditions, and regulatory references related to the stock incentive plan. The document is not a financial report, earnings release, or management discussion but a legal opinion on a specific equity incentive plan. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal filing related to corporate governance and equity incentive plans, not a direct report of financial results or management changes. The document length (15,000 characters) and content confirm it is a full legal opinion, not a brief announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-02-11 Chinese
2026年限制性股票激励计划自查表
Regulatory Filings Classification · 95% confidence The document is a detailed compliance self-checklist related to a 2026 restricted stock incentive plan for a company. It includes numerous compliance confirmations, regulatory references, and internal governance checks related to stock incentive plans. There are no financial statements, earnings data, or audit opinions presented as a standalone audit report. The document is not an announcement of a report but a compliance checklist likely submitted to regulators or used internally to confirm adherence to stock incentive regulations. This type of document fits best under Regulatory Filings (RNS) as it is a compliance-related filing that does not fall under other specific categories like Annual Report, Audit Report, or Capital Update.
2026-02-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.